Blockade of angiotensin II type 1 receptors:: Effect on carotid and radial artery structure and function in hypertensive humans

被引:41
作者
Benetos, A
Gautier, S
Laflèche, A
Topouchian, J
Frangin, G
Girerd, X
Sissmann, J
Safar, ME
机构
[1] Hop Broussais, Dept Internal Med, F-75674 Paris 14, France
[2] Hop Broussais, INSERM, U337, F-75674 Paris, France
关键词
hypertension; large-artery structure and function; AT(1)-receptor blockade;
D O I
10.1159/000025708
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Converting-enzyme inhibition reduces cardiovascular hypertrophy in hypertensive subjects. Whether the blockade of angiotensin II type 1 (AT(1)) receptors reduces arterial hypertrophy has never been investigated. In a double-blind study versus placebo in subjects with essential hypertension, the effect of the AT(1) blocker irbesartan (150 mg/day for 8 weeks) on blood pressure, wall thickness, diameter and stiffness of the common carotid and radial arteries was studied, using echotracking techniques of high resolution. With irbesartan, mean blood pressure decreased significantly and proportionally to the baseline levels of active renin, and angiotensin I and II. There was a significant decrease in radial artery wall thickness. The percent change from baseline (+/- SEM) was -10.51 +/- 3.42 versus 6.18 +/- 4.77. There was no significant change in diameter or distensibility. This effect was correlated neither to blood pressure changes nor to hormonal baseline levels of the renin-angiotensin system. Carotid wall thickness and diameter were unchanged. Thus a 2-month treatment with an AT(1) antagonist significantly reduced radial but not carotid artery wall thickness. Blood pressure reduction could be explained on the basis of circulating renin-angiotensin activity. On the contrary, radial artery wall thickness reduction was independent of the baseline circulating renin-angiotensin activity and was not correlated with the effects of AT(1) blockade on blood pressure, thus implying the involvement of local hemodynamic and/or cellular mechanisms. Copyright (C)2000 S. Karger AG, Basel.
引用
收藏
页码:8 / 15
页数:8
相关论文
共 32 条
  • [1] ANGIOTENSIN-CONVERTING ENZYME-INHIBITION PREVENTS THE INCREASE IN AORTIC COLLAGEN IN RATS
    ALBALADEJO, P
    BOUAZIZ, H
    DURIEZ, M
    GOHLKE, P
    LEVY, BI
    SAFAR, ME
    BENETOS, A
    [J]. HYPERTENSION, 1994, 23 (01) : 74 - 82
  • [2] [Anonymous], 1994, Textbook of Hypertension
  • [3] Role of angiotensin II and bradykinin on aortic collagen following converting enzyme inhibition in spontaneously hypertensive rats
    Benetos, A
    Levy, BI
    Lacolley, P
    Taillard, F
    Duriez, M
    Safar, ME
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) : 3196 - 3201
  • [4] Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients
    Benetos, A
    Gautier, S
    Ricard, S
    Topouchian, J
    Asmar, R
    Poirier, O
    Larosa, E
    Guize, L
    Safar, M
    Soubrier, F
    Cambien, F
    [J]. CIRCULATION, 1996, 94 (04) : 698 - 703
  • [5] PLASMA ANGIOTENSIN-CONVERTING ENZYME-ACTIVITY AND CAROTID WALL THICKENING
    BONITHONKOPP, C
    DUCIMETIERE, P
    TOUBOUL, PJ
    FEVE, JM
    BILLAUD, E
    HERAUD, V
    [J]. CIRCULATION, 1994, 89 (03) : 952 - 954
  • [6] NON-INVASIVE ESTIMATION OF CENTRAL AORTIC PRESSURE USING THE OSCILLOMETRIC METHOD FOR ANALYZING SYSTEMIC ARTERY PULSATILE BLOOD-FLOW - COMPARATIVE-STUDY OF INDIRECT SYSTOLIC, DIASTOLIC, AND MEAN BRACHIAL-ARTERY PRESSURE WITH SIMULTANEOUS DIRECT ASCENDING AORTIC PRESSURE MEASUREMENTS
    BOROW, KM
    NEWBURGER, JW
    [J]. AMERICAN HEART JOURNAL, 1982, 103 (05) : 879 - 886
  • [7] BRUNNER HR, 1997, AM J HYPERTENS, V10, P311
  • [8] RECEPTOR-MEDIATED EFFECTS OF ANGIOTENSIN-II ON GROWTH OF VASCULAR SMOOTH-MUSCLE CELLS FROM SPONTANEOUSLY HYPERTENSIVE RATS
    BUNKENBURG, B
    VANAMELSVOORT, T
    ROGG, H
    WOOD, JM
    [J]. HYPERTENSION, 1992, 20 (06) : 746 - 754
  • [9] DELETION POLYMORPHISM IN THE GENE FOR ANGIOTENSIN-CONVERTING ENZYME IS A POTENT RISK FACTOR FOR MYOCARDIAL-INFARCTION
    CAMBIEN, F
    POIRIER, O
    LECERF, L
    EVANS, A
    CAMBOU, JP
    ARVEILER, D
    LUC, G
    BARD, JM
    BARA, L
    RICARD, S
    TIRET, L
    AMOUYEL, P
    ALHENCGELAS, F
    SOUBRIER, F
    [J]. NATURE, 1992, 359 (6396) : 641 - 644
  • [10] CAZAUBON C, 1993, J PHARMACOL EXP THER, V265, P826